Rockwell Medical, Inc.
RMTI Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$6.94
KIRA · Stoqly’s AI analyst, in plain words
- Rockwell Medical, Inc. had $69.3M of revenue in fiscal 2025, down 31.8% on the year before. Over five years, revenue changed +2.2% a year on average.
- Its operating margin was −6.8%, down 7.4 pts: of every 100 in sales, about −7 is left after running the business.
- Rockwell Medical, Inc. lost $5.3M in fiscal 2025.
- Free cash flow was −$1.2M in fiscal 2025, −1.7% of revenue.
- Rockwell Medical, Inc. has $15.4M more cash than debt.
Market cap
$27.5M
P/E
—
Revenue
$69.3M
Net income
−$5.3M
Free cash flow
−$1.2M
Operating margin
−6.8%
Rockwell Medical, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−31.8%
No. Sales fell 31.8% last year.
Does it make a profit?
−7.7%
No. It lost money last year.
Does profit turn into cash?
−1.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Rockwell Medical, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- ROCKWELL MEDICAL, INC.
- CIK
- 0001041024
Rockwell Medical, Inc. · RMTI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $61.9M | $72.8M | $83.6M | $101M | $69.3M |
| Revenue growth | −0.4% | 17.6% | 14.8% | 21.4% | −31.8% |
| Gross margin | −3.9% | 5.6% | 10.4% | 17.2% | 16.9% |
| Operating margin | −49.0% | −23.0% | −8.0% | 0.6% | −6.8% |
| Net income | −$32.7M | −$18.7M | −$8.4M | −$0.5M | −$5.3M |
| Net margin | −52.8% | −25.7% | −10.1% | −0.5% | −7.7% |
| Diluted EPS | −$3.83 | −$1.31 | −$0.37 | −$0.03 | −$0.15 |
| Cash | |||||
| Cash from operations | −$33.5M | −$16.9M | −$9.4M | $4.2M | −$0.7M |
| Capital expenditure | — | — | $0.3M | $1.0M | $0.5M |
| Free cash flow | — | — | −$9.7M | $3.2M | −$1.2M |
| FCF margin | — | — | −11.6% | 3.1% | −1.7% |
| Share count change | −88.7% | 67.8% | 63.0% | 33.2% | 15.8% |
| Debt and strength | |||||
| Cash and short-term investments | $22.4M | $21.5M | $10.9M | $21.6M | $25.0M |
| Debt incl. finance leases | $23.7M | $11.8M | $10.4M | $10.0M | $9.6M |
| Shareholders' equity | $2.5M | $14.1M | $21.3M | $32.6M | $37.0M |
| Net debt / EBITDA | — | — | — | −4.2x | — |
| Current ratio | 1.7x | 2.0x | 1.7x | 2.6x | 4.0x |
| Interest coverage | −12.9x | −8.7x | −2.9x | 0.5x | −4.2x |
| Returns and quality | |||||
| Return on capital | −3,609.3% | −736.5% | −28.3% | 2.5% | −17.8% |
| Return on equity | −178.0% | −224.5% | −47.7% | −1.8% | −15.3% |
| Return on tangible equity | −2,024.4% | −141.7% | −89.4% | −3.6% | −20.7% |
| Piotroski F-score | 2 | 6 | 4 | 7 | 2 |
| Altman Z'' | −27.0 | −26.7 | −23.4 | −18.0 | −18.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
4 insiders
Of sales under plans
72%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rockwell Medical, Inc. · RMTI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.94 a share, the company is worth $27.5M.
Source: SEC EDGAR XBRL filings (CIK 0001041024). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.